mRNA 1345
Alternative Names: mRESVIA; mRNA-1345; Respiratory syncytial virus vaccine - Moderna TherapeuticsLatest Information Update: 21 Aug 2025
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Respiratory syncytial virus infections
- Phase I Metapneumovirus infections
Most Recent Events
- 05 Aug 2025 Moderna Therapeutics initiates a phase III trial in Respiratory Syncytial Virus (Prevention) in the US (IM) (NCT07117487)
- 27 Jun 2025 Moderna completes a phase II trial for Respiratory syncytial virus infections (In children, In adolescents, Prevention) in USA, Panama (IM, Injection)(NCT06097299)
- 12 Jun 2025 FDA approves mRNA-1345 for Respiratory syncytial virus infections (In adults, Monotherapy, Prevention) in USA